Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 8Genitourinary 3Gastrointestinal 3Thoracic 2Gynecologic 2CNS 2Other solid neoplasm 1NET 1Endocrine 1Dermatologic 1Breast 1

Conditions

Vipoma 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Gastrinoma 1Carcinoma 1Carcinoid Tumor 1

Interventions

Everolimus 18lutetium Lu 177 dotatate 9lanreotide 8surufatinib 7Octreotide 7pasireotide 5amino-acid, glucose, and electrolyte solution 5Sunitinib 5Temozolomide 4Data Collection 4pembrolizumab 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2fosbretabulin 2arginyllysine 2anlotinib 2Paclitaxel 2PM 01183 2Lutetium-177 2Lutetium 2Irinotecan 2Injections 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × epothilone B × NET × Clear all
NCT00050349 2017-03-01

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Novartis

Phase 2 Completed
33 enrolled
EndocrineNET

Carcinoid Tumor, Carcinoma, Vipoma, Neoplasm Metastasis, Neoplasms, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡